The FDA has not added blood clots to the semaglutide label but is investigating the signal
Semaglutide Not Associated with Increased Risk of Eye Disorders, 19 August 2025, The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION), 27 June 2025, WHO, PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, 06 June 2025, European Medicine Agency, Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan, does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy
It is a modified version of the natural IGF-1 hormone your body produces
A postmenopausal woman without hormone replacement may benefit from dosing at the higher end of the range, reflecting the loss of endogenous MOTS-c-promoting estrogen signaling
30 .